Stay updated on Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.

Latest updates to the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page
- Check5 days agoChange DetectedSite revision updated to v3.4.3, replacing the prior Revision: v3.4.2.SummaryDifference0.0%

- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedFooter now displays Revision: v3.4.2 and the older government funding/operating status notices (v3.4.1) have been removed.SummaryDifference0.4%

- Check41 days agoChange DetectedNotice about a lapse in government funding and the NIH Clinical Center's operating status added; site revision updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check48 days agoChange DetectedUI and metadata updates include a glossary toggle, a new label 'Last Update Submitted that Met QC Criteria' for QC status, capitalization changes for 'No FEAR Act Data', and a new page revision indicator 'Revision: v3.4.0'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page shows a revision update from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check84 days agoChange DetectedAdded new study locations: Fujian, Gansu, Heilongjiang, Henan, Shandong, Sichuan, Tianjin Municipality, Zhejiang (China) and Gyeonggi-do, Seoul Teugbyeolsi (South Korea). Updated revision tag from v3.3.2 to v3.3.3.SummaryDifference1%

Stay in the know with updates to Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety Tislelizumab Fruquintinib Combo Clinical Trial page.